Industry News

Indian drug manufacturers benefit from Big Pharma interest beyond China

Pradip Mahajan Mon, 11/27/2023 - 16:09
Drugmakers are seeking to limit their reliance on Chinese contractors who produce drugs used in clinical trials and early-stage manufacturing, a move that is benefiting rivals in India, according to interviews with 10 industry executives and experts.
Cell Biology Lab inaugurated at Kumar Organic Products Research Centre

Rajesh Vagh Fri, 11/17/2023 - 17:00
Cell Biology Lab was inaugurated at Kumar Organic Products Research Centre on 15th November 2023 by Prof. Dr. Samir K Brahmachari , Former Director General, CSIR.
Biocon Biologics receives MHRA, UK Approval for YESAFILI, Biosimilar Aflibercept

Rajesh Vagh Fri, 11/17/2023 - 16:54
Biocon Biologics Limited a subsidiary of Biocon Ltd. has announced that MHRA, Medicines and Healthcare products Regulatory Agency in the UK, has granted marketing authorization for YESAFILI®, a biosimilar of Aflibercept.

In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU).
First oral postpartum depression treatment to cost USD 15,900

Rajesh Vagh Wed, 11/08/2023 - 15:48
Sage Therapeutics has priced the oral postpartum depression medicine at USD 15,900 for a full 14-day course of treatment which is developed with Biogen. The pricing of medicine has been announced recently, whereas the drug was approved by the FDA in August.
4 November 2023

Zydus and Lupin sign licensing agreement for co-marketing of Saroglitazar Mg

Zydus Lifesciences Limited a discovery-driven, global lifesciences company and Lupin Limited (Lupin), a global pharma major, announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces the pill burden and offers the patient more convenience.
1 November 2023

Zydus acquires UK based LiqMeds Group

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
31 October 2023

Sun Pharma and Zydus sign licensing agreement for co-marketing of Desidustat

Sun Pharmaceutical Industries Limited and Zydus Lifesciences Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India. Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease (CKD) in India.
27 October 2023

Eisai shows trial results for LEQEMBI

Eisai Co., Ltd and Biogen Inc. announced today that Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 Lecanemab for Early Alzheimer's Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration" at the 16th annual Clinical Trials on Alzheimer's Disease (CTAD) conference held in Boston, Massachusetts, United States and virtually October 24-27, 2023.
16 October 2023

Sun Pharma skin cancer medicine meets endpoint in phase 3 trial

Philogen S.p.A and Sun Pharmaceutical Industries Limited are pleased to announce positive results from the Phase III PIVOTAL trial in patients with locally advanced fully resectable melanoma (NCT02938299). The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm). Patients were allowed to receive approved adjuvant systemic therapies after surgery in both arms.
16 October 2023

Venus Remedies gets marketing approval for six chemotherapy drugs from the Philippines

Building upon its sizeable presence in the oncology space in the Association of Southeast Asian Nations (ASEAN) region, Venus Remedies Ltd, a well-known provider of affordable cancer drugs worldwide, has received marketing approval from the Philippines, the second largest ASEAN market, for six key chemotherapy drugs.